ANTI-IGF-I RECEPTOR HUMANIZED ANTIBODY

• Main Authors: EGUCHI, HIROSHI, OHORI, MASAYO, TAKAGI, KENICHIRO, NAMIKI, NAOKO, HIGUCHI, HIROFUMI, YAMAMURA, SATOSHI, TANOKURA, AKIRA, KATO, HIROTSUGU, ISHIKAWA, DAISUKE, TAKEO, TOMOYO
• Format: Patent
• Language: English; French
• Published: 11.06.2020
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

Provided is a humanized antibody that, through IGF-I receptor, increases muscle mass but does not lower the blood glucose level. This humanized antibody: is an anti-IGF-I receptor humanized antibody, a fragment thereof, or a derivative thereof; has a specific amino acid sequence such as SEQ ID NOs: 1 to 6 serving as a CDR sequence; and specifically binds to IGF-I receptor extracellular domain. L'invention concerne un anticorps humanisé qui, par l'intermédiaire du récepteur de l'IGF-I, augmente la masse musculaire mais ne diminue pas le taux de glycémie. Cet anticorps humanisé : est un anticorps humanisé anti-récepteur de l'IGF-I, un fragment de celui-ci ou un dérivé de celui-ci; a une séquence d'acides aminés spécifique telle que les SEQ ID No. : 1 à 6 servant de séquence de CDR; et se lie spécifiquement au domaine extracellulaire du récepteur de l'IGF-I.